189 related articles for article (PubMed ID: 26978596)
1. Activation of AMPK Prevents Monocrotaline-Induced Extracellular Matrix Remodeling of Pulmonary Artery.
Li S; Han D; Zhang Y; Xie X; Ke R; Zhu Y; Liu L; Song Y; Yang L; Li M
Med Sci Monit Basic Res; 2016 Mar; 22():27-33. PubMed ID: 26978596
[TBL] [Abstract][Full Text] [Related]
2. Activation of AMPK prevents monocrotaline-induced pulmonary arterial hypertension by suppression of NF-κB-mediated autophagy activation.
Zhai C; Shi W; Feng W; Zhu Y; Wang J; Li S; Yan X; Wang Q; Zhang Q; Chai L; Li C; Liu P; Li M
Life Sci; 2018 Sep; 208():87-95. PubMed ID: 30009823
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of HDAC1 alleviates monocrotaline-induced pulmonary arterial remodeling through up-regulation of miR-34a.
Li F; Wang D; Wang H; Chen L; Sun X; Wan Y
Respir Res; 2021 Aug; 22(1):239. PubMed ID: 34465322
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of ubiquitin proteasome function prevents monocrotaline-induced pulmonary arterial remodeling.
Zhu Y; Wu Y; Shi W; Wang J; Yan X; Wang Q; Liu Y; Yang L; Gao L; Li M
Life Sci; 2017 Mar; 173():36-42. PubMed ID: 28212825
[TBL] [Abstract][Full Text] [Related]
5. 4-Chloro-DL-phenylalanine protects against monocrotaline‑induced pulmonary vascular remodeling and lung inflammation.
Bai Y; Wang HM; Liu M; Wang Y; Lian GC; Zhang XH; Kang J; Wang HL
Int J Mol Med; 2014 Feb; 33(2):373-82. PubMed ID: 24337018
[TBL] [Abstract][Full Text] [Related]
6. Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats.
Yang PS; Kim DH; Lee YJ; Lee SE; Kang WJ; Chang HJ; Shin JS
Respir Res; 2014 Nov; 15():148. PubMed ID: 25420924
[TBL] [Abstract][Full Text] [Related]
7. Metformin Prevents Progression of Experimental Pulmonary Hypertension via Inhibition of Autophagy and Activation of Adenosine Monophosphate-Activated Protein Kinase.
Liu Y; Xu Y; Zhu J; Li H; Zhang J; Yang G; Sun Z
J Vasc Res; 2019; 56(3):117-128. PubMed ID: 31085922
[TBL] [Abstract][Full Text] [Related]
8. Serum-glucocorticoid regulated kinase 1 regulates macrophage recruitment and activation contributing to monocrotaline-induced pulmonary arterial hypertension.
Xi X; Liu S; Shi H; Yang M; Qi Y; Wang J; Du J
Cardiovasc Toxicol; 2014 Dec; 14(4):368-78. PubMed ID: 24825325
[TBL] [Abstract][Full Text] [Related]
9. Thymoquinone attenuates monocrotaline-induced pulmonary artery hypertension via inhibiting pulmonary arterial remodeling in rats.
Zhu N; Zhao X; Xiang Y; Ye S; Huang J; Hu W; Lv L; Zeng C
Int J Cardiol; 2016 Oct; 221():587-96. PubMed ID: 27420584
[TBL] [Abstract][Full Text] [Related]
10. [Changes of MMP-2,9 and TIMP-1 expressions in rats with pulmonary arterial hypertension after captopril and losartan interventions].
Wang XM; Zhou TF; Liu B; Wei L; Shi K; Zhao SS; Hua YM; Liu HM
Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Mar; 40(2):255-9. PubMed ID: 19462901
[TBL] [Abstract][Full Text] [Related]
11. Dihydromyricetin prevents monocrotaline-induced pulmonary arterial hypertension in rats.
Li Q; Wang J; Zhu X; Zeng Z; Wu X; Xu Y; Xie J; Yu J
Biomed Pharmacother; 2017 Dec; 96():825-833. PubMed ID: 29078260
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Notch3 prevents monocrotaline-induced pulmonary arterial hypertension.
Zhang Y; Xie X; Zhu Y; Liu L; Feng W; Pan Y; Zhai C; Ke R; Li S; Song Y; Fan Y; Fan F; Wang X; Li F; Li M
Exp Lung Res; 2015; 41(8):435-43. PubMed ID: 26317171
[TBL] [Abstract][Full Text] [Related]
13. Visceral adipose tissue-derived serine protease inhibitor prevents the development of monocrotaline-induced pulmonary arterial hypertension in rats.
Sakamoto Y; Kameshima S; Kakuda C; Okamura Y; Kodama T; Okada M; Yamawaki H
Pflugers Arch; 2017 Nov; 469(11):1425-1432. PubMed ID: 28776262
[TBL] [Abstract][Full Text] [Related]
14. Salvianolic acid A attenuates vascular remodeling in a pulmonary arterial hypertension rat model.
Chen YC; Yuan TY; Zhang HF; Wang DS; Yan Y; Niu ZR; Lin YH; Fang LH; Du GH
Acta Pharmacol Sin; 2016 Jun; 37(6):772-82. PubMed ID: 27180980
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic effects of baicalin on monocrotaline-induced pulmonary arterial hypertension by inhibiting inflammatory response.
Luan Y; Chao S; Ju ZY; Wang J; Xue X; Qi TG; Cheng GH; Kong F
Int Immunopharmacol; 2015 May; 26(1):188-93. PubMed ID: 25601497
[TBL] [Abstract][Full Text] [Related]
16. Calorie Restriction Attenuates Monocrotaline-induced Pulmonary Arterial Hypertension in Rats.
Ding M; Lei J; Qu Y; Zhang H; Xin W; Ma F; Liu S; Li Z; Jin F; Fu E
J Cardiovasc Pharmacol; 2015 Jun; 65(6):562-70. PubMed ID: 25636073
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Siah2 ubiquitin ligase ameliorates monocrotaline-induced pulmonary arterial remodeling through inactivation of YAP.
Wang Q; Shi W; Zhang Q; Feng W; Wang J; Zhai C; Yan X; Li M
Life Sci; 2020 Feb; 242():117159. PubMed ID: 31837334
[TBL] [Abstract][Full Text] [Related]
18. The extracellular signal-regulated kinase is involved in the effects of sildenafil on pulmonary vascular remodeling.
Zeng Z; Li Y; Jiang Z; Wang C; Li B; Jiang W
Cardiovasc Ther; 2010; 28(1):23-9. PubMed ID: 20074256
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of matrix metalloproteinases by lung TIMP-1 gene transfer limits monocrotaline-induced pulmonary vascular remodeling in rats.
Vieillard-Baron A; Frisdal E; Raffestin B; Baker AH; Eddahibi S; Adnot S; D'Ortho MP
Hum Gene Ther; 2003 Jun; 14(9):861-9. PubMed ID: 12828857
[TBL] [Abstract][Full Text] [Related]
20. Ranolazine prevents INaL enhancement and blunts myocardial remodelling in a model of pulmonary hypertension.
Rocchetti M; Sala L; Rizzetto R; Staszewsky LI; Alemanni M; Zambelli V; Russo I; Barile L; Cornaghi L; Altomare C; Ronchi C; Mostacciuolo G; Lucchetti J; Gobbi M; Latini R; Zaza A
Cardiovasc Res; 2014 Oct; 104(1):37-48. PubMed ID: 25139747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
